medigraphic.com

2015, Número S1

<< Anterior Siguiente >>

Rev Mex Anest 2015; 38 (S1)


Seguridad en productos hemáticos, anticoagulantes orales y agentes antiplaquetarios

Portela-Ortiz JM, Delgadillo-Arauz C, Hernández-Cortés C

Idioma: Español
Referencias bibliográficas: 54
Paginas: 356-363
Archivo PDF: 189.81 Kb.


FRAGMENTO

Seguridad en transfusión de productos hemáticos
De los 85 millones de productos hemáticos transfundidos al año el 40% de ellos son utilizados en pacientes quirúrgicos; si bien la base de evidencia aún es incompleta para el uso de concentrados eritrocitarios, la mayoría apoya la estrategia restrictiva; ésta se ha visto asociada con una disminución en infecciones nosocomiales; en pacientes con comorbilidades el umbral para transfundir aún es desconocido y es materia de investigación.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Mallett SV, Armstrong M. Point-of-care monitoring of haemostasis. Anaesthesia. 2015;70:73-77.

  2. Retter A, Wyncoll D. Guidelines on the management of anaemia and red cell transfusion in adult critically ill patients. British Journal of Haematology. 2013;160:445-464.

  3. Spahn DR, Smith LR, Schell RM, Hoffman RD, Gillespie R, Leone BJ. Importance of severity of coronary artery disease for the tolerance to normovolemic hemodilution. Comparison of single-vessel versus multivessel stenoses in a canine model. J Thorac Cardiovasc Surg. 1994;108:231-239.

  4. Pont-Thibodeau GD, Harrington K, Lacroix J. Anemia and red blood cell transfusion in critically ill cardiac patients. Annals of Intensive Care. 2014;4:16.

  5. Hebert PC, Wells G, Blajchman MA, et al. A multicenter randomized controlled clinical trial of transfusion requirements in critical care. N Engl J Med. 1999;340:409-417.

  6. Kozek-Langenecker SA, Afshari A, Albaladejo P, Santullano CA, De Robertis E, Filipescu DC, et al. Management of severe perioperative bleeding guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol. 2013;30:270-382.

  7. Carless PA, Henry DA, Carson JL, Hebert PP, McClelland B, Ker K. Transfusion thresholds and other strategies for guiding allogeneic redblood cell transfusion. Cochrane Database Syst Rev. 2010;CD002042.

  8. American Society of Anesthesiologists Task Force on Perioperative Blood Management. Practice guidelines for perioperative blood management: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Management. Anesthesiology. 2015;122:241-275.

  9. Yasaka M, Sakata T, Naritomi H, Minematsu K. Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation. Thromb Res. 2005;115:455-459.

  10. Yasaka M, Sakata T, Naritomi H, Minematsu K. Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation. Thromb Res. 2005;115:455-459.

  11. Kalina U, Bickhard H, Schulte S. Biochemical comparison of seven commercially available prothrombin complex concentrates. Int J Clin Pract. 2008;82:1614-1622.

  12. Kor DJ, Stubbs JR, Gajic O. Perioperative coagulation management-fresh frozen plasma. Best Practice & Research Clinical Anesthesiology. 2010;24:51-64.

  13. Holland LL, Foster TM, Marlar RA, Brooks JP. Fresh frozen plasma is an effective for correcting minimally elevated international normalized ratios. Transfusion. 2005;45:1234-1235.

  14. Makris M, Greaves M, Phillips WS, Kitchen S, Rosendaal FR, Preston EF. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Hemost. 1997;77:477-480.

  15. Bruce D, Nokes TJC. Prothrombin complex concentrate (Beriplex P/N) in severe bleeding: experience in a large tertiary hospital. Crit Care. 2008;12:R105.

  16. Sorensen S, Spahn DR, Innerhofer P, Spannagl M, Rossaint R. Clinical review: prothrombin complex concentrates evaluation of safety and thrombogenicity. Critical Care. 2011;15:201-209.

  17. Weisel JW. Fibrinogen and fibrin. Adv Protein Chem. 2005;70:247-299.

  18. Levy JH, Goodnough LT. How I use fibrinogen replacement therapy in acquired bleeding. Blood. 2015;125:1387-1393.

  19. Levy JH, Goodnough LT. How I use fibrinogen replacement therapy in acquired bleeding. Blood. 2015;125:1387-1393.

  20. Goodnough LT, Levy JH, Murphy MF. Concepts of blood transfusion in adults. Lancet. 2013;381:1845-1854.

  21. Murad MH, Stubbs JR, Gandhi MJ, et al. The effect of plasma transfusion on morbidity and mortality: a systematic review and metaanalysis. Transfusion. 2010;50:1370-1383.

  22. Chowdary P, Saayman AG, Paulus U, Findlay GP, Collins PW. Efficacy of standard dose and 30 ml/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients. Br J Haematol. 2004;125:69-73.

  23. Kozek-Langenecker S, Sørensen B, Hess JR, Spahn DR. Clinical effectiveness of fresh frozen plasma compared with fibrinogen concentrate: a systematic review. Crit Care. 2011;15:R239.

  24. Kasper CK. Judith graham pool and the discovery of cryoprecipitate. Haemophilia. 2012;18:833-835.

  25. Stanworth SJ. The evidence-based use of FFP and cryoprecipitate for abnormalities of coagulation tests and clinical coagulopathy. Hematology Am Soc Hematol Educ Program. 2007;2007:179-186.

  26. Pereira A. Cryoprecipitate versus commercial fibrinogen concentrate in patients who occasionally require a therapeutic supply of fibrinogen: risk comparison in the case of an emerging transfusion-transmitted infection. Haematologica. 2007;92:846-849.

  27. Gröner A. Reply. Pereira A. Cryoprecipitate versus commercial fibrinogen concentrate in patients who occasionally require a therapeutic supply of fibrinogen: risk comparison in the case of an emerging transfusion-transmitted infection. Haematologica 2007;92:846-9. Haematologica. 2008;93:e24-e26; author reply e27.

  28. Kozek-Langenecker SA, Afshari A, Albaladejo P, Santullano CA, De Robertis E, Filipescu DC, et al. Management of severe perioperative bleeding guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol. 2013;30:270-382.

  29. Levy JH, Welsby I, Goodnough LT. Fibrinogenas a therapeutic target for bleeding: a review of critical levels and replacement therapy. Transfusion. 2014;54:1389-1405, quiz 1388.

  30. Franchini M, Lippi G. Fibrinogen replacement therapy: a critical review of the literature. Blood Transfus. 2012;10:23-27.

  31. Brenni M, Worn M, Brüesch M, Spahn DR, Ganter MT. Successful rotational thromboelastometry-guided treatment of traumatic haemorrhage, hyperfibrinolysis and coagulopathy. Acta Anaesthesiol Scand. 2010;54:111-117.

  32. Nuttall GA, Oliver WC, Santrach PJ, et al. Efficacy of a simple intraoperative transfusion algorithm for nonerythrocyte component utilization after cardiopulmonary bypass. Anesthesiology. 2001;94:773-781; discussion 5A-6A.

  33. Karlsson M, Ternström L, Hyllner M, et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery. A prospective randomised pilot study. Thromb Haemost. 2009;102:137-144.

  34. Solomon C, Schöchl H, Hanke A, et al. Haemostatic therapy in coronary artery bypass graft patients with decreased platelet function: comparison of fibrinogen concentrate with allogeneic blood products. Scand J Clin Lab Invest. 2012;72:121-128.

  35. Charbit B, Mandelbrot L, Samain E, et al.; PPH Study Group. The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage. J Thromb Haemost. 2007;5:266-273.

  36. De Lloyd L, Bovington R, Kaye A, et al. Standard haemostatic tests following major obstetric haemorrhage. Int J Obstet Anesth. 2011;20:135-141.

  37. Tengborn L, Blombäck M, Berntorp E. Tranexamic acid-an old drug still going strong and making a revival. Thromb Res. 2015;135:231-242.

  38. Williams-Johnson JA, McDonald AH, Strachan GG, Williams EW. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2) A randomised, placebo-controlled trial. West Indian Med J. 2010;59:612-624.

  39. Ducloy-Bouthors AS, Jude B, Duhamel A, Broisin F, Huissoud C, Keita-Meyer H, et al. High-dose tranexamic acid reduces blood loss in postpartum haemorrhage. Crit Care. 2011;15:R117.

  40. Frachon X, Pommereuil M, Berthier AM, Lejeune S, Hourdin-Eude S, Quero J, et al. Management options for dental extraction in hemophiliacs: a study of 55 extractions (2000-2002). Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;99:270-275.

  41. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005; 99:270–5.

  42. Roberts LN, Patel RK, Arya R. Haemostasis and thrombosis in liver disease. Br J Haematol. 2010;148:507-521.

  43. Lisman T, Bakhtiari K, Adelmeijer J, Meijers JC, Porte RJ, Stravitz RT. Intact thrombin generation and decreased fibrinolytic capacity in patients with acute liver injury or acute liver failure. J Thromb Haemost. 2012;10:1312-1329.

  44. Agarwal A, Sharma N, Vij V. Point-of-care coagulation monitoring during liver transplantation. Trends Anaesth Crit Care. 2013;3:42-48.

  45. Eikelboom JW, Weitz JI. New anticoagulants. Circulation. 2010;121:1523-32.

  46. Levy JH, Faraoni D, Spring JL, Douketis JD, Samama CM. Managing new oral anticoagulants in the perioperative and intensive care unit setting. Anesthesiology. 2013;118:1466-1474.

  47. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet. 2009;48:1-22.

  48. Khadzhynov D, Wagner F, Formella S, Wiegert E, Moschetti V, Slowinski T, Neumayer HH, Liesenfeld KH, Lehr T, Hartter S, Friedman J, Peters H, Clemens A: Effective elimination of dabigatran by haemodialysis: A phase I single-centre study in patients with end-stage renal disease. Thromb Haemost 2013 Feb 7; 109 .

  49. Stangier J, Stähle H, Rathgen K, Roth W, Shakeri-Nejad K: Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. J Clin Pharmacol 2008; 48:1411

  50. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet. 2009;48:1-22.

  51. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358:2765-2775.

  52. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents . JAMA. 2005;293:2126-2130.

  53. Robless P, Mikhailidis DP, Stansby G. Systematic review of antiplatelet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease. Br J Surg. 2001;88:787-800.

  54. Darvish-Kazem S, Gandhi M, Marcucci M, Douketis JD. Perioperative management of antiplatelet therapy in patients with a coronary stent who need noncardiac surgery: a systematic review of clinical practice guidelines. Chest. 2013;144:1848-1856.




2020     |     www.medigraphic.com